Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedApr 23, 2026

DataAggregated Company Financials

Companies7

7D-4.7%
3M-7.5%
1Y-5.4%
YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 4.7%, driven by a pullback from Lonza Group of 4.8%. The industry has fallen 5.4% in the last year. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 24 Apr 2026	CHF 47.3b	CHF 10.1b	CHF 1.1b	34.1x	41.4x	4.7x
Sun, 22 Mar 2026	CHF 44.0b	CHF 10.1b	CHF 1.1b	31.1x	38.5x	4.3x
Tue, 17 Feb 2026	CHF 49.5b	CHF 10.1b	CHF 1.3b	30.8x	38.8x	4.9x
Thu, 15 Jan 2026	CHF 52.2b	CHF 10.6b	CHF 1.1b	33.8x	47.5x	4.9x
Sat, 13 Dec 2025	CHF 47.0b	CHF 10.6b	CHF 1.1b	27.6x	42.8x	4.4x
Mon, 10 Nov 2025	CHF 48.0b	CHF 10.6b	CHF 1.1b	27.8x	43.7x	4.5x
Wed, 08 Oct 2025	CHF 50.3b	CHF 10.6b	CHF 1.1b	32.4x	45.8x	4.7x
Fri, 05 Sep 2025	CHF 53.4b	CHF 10.7b	CHF 1.1b	33.3x	48.4x	5x
Sun, 03 Aug 2025	CHF 54.2b	CHF 10.7b	CHF 1.1b	34.6x	47.2x	5.1x
Tue, 01 Jul 2025	CHF 52.6b	CHF 10.1b	CHF 1.0b	33.3x	50.7x	5.2x
Thu, 29 May 2025	CHF 52.3b	CHF 10.1b	CHF 1.0b	31.6x	50.3x	5.2x
Sat, 26 Apr 2025	CHF 52.4b	CHF 10.1b	CHF 1.0b	29.7x	51.1x	5.2x
Mon, 24 Mar 2025	CHF 53.6b	CHF 10.1b	CHF 1.0b	33.1x	52.6x	5.3x
Wed, 19 Feb 2025	CHF 56.2b	CHF 10.1b	CHF 1.0b	35.5x	55.8x	5.6x
Fri, 17 Jan 2025	CHF 53.5b	CHF 10.2b	CHF 943.4m	34.7x	56.7x	5.2x
Sun, 15 Dec 2024	CHF 53.1b	CHF 10.2b	CHF 943.5m	38.6x	56.3x	5.2x
Tue, 12 Nov 2024	CHF 56.2b	CHF 10.2b	CHF 943.4m	44x	59.6x	5.5x
Thu, 10 Oct 2024	CHF 54.6b	CHF 10.2b	CHF 943.4m	41.3x	57.8x	5.3x
Sat, 07 Sep 2024	CHF 55.6b	CHF 10.2b	CHF 937.2m	43x	59.3x	5.4x
Mon, 05 Aug 2024	CHF 57.4b	CHF 10.2b	CHF 924.3m	44.5x	62.1x	5.6x
Wed, 03 Jul 2024	CHF 51.2b	CHF 10.3b	CHF 1.0b	43.8x	51.1x	5x
Fri, 31 May 2024	CHF 52.4b	CHF 10.3b	CHF 1.0b	43.7x	52.3x	5.1x
Sun, 28 Apr 2024	CHF 55.2b	CHF 10.3b	CHF 1.0b	43.8x	55.1x	5.4x
Tue, 26 Mar 2024	CHF 57.1b	CHF 10.2b	CHF 1.0b	46.3x	56.9x	5.6x
Thu, 22 Feb 2024	CHF 49.5b	CHF 10.2b	CHF 1.0b	46x	48.6x	4.9x
Sat, 20 Jan 2024	CHF 41.2b	CHF 9.8b	CHF 1.5b	30.8x	27.6x	4.2x
Mon, 18 Dec 2023	CHF 41.2b	CHF 9.8b	CHF 1.5b	32.6x	27.6x	4.2x
Wed, 15 Nov 2023	CHF 41.0b	CHF 9.8b	CHF 1.5b	28.6x	27.4x	4.2x
Fri, 13 Oct 2023	CHF 47.0b	CHF 9.8b	CHF 1.5b	31.8x	31.5x	4.8x
Sun, 10 Sep 2023	CHF 51.9b	CHF 9.8b	CHF 1.5b	35.7x	34.8x	5.3x
Tue, 08 Aug 2023	CHF 52.7b	CHF 9.8b	CHF 1.5b	35.8x	34.1x	5.4x
Thu, 06 Jul 2023	CHF 55.1b	CHF 9.7b	CHF 1.6b	35.9x	33.7x	5.7x
Sat, 03 Jun 2023	CHF 61.1b	CHF 9.7b	CHF 1.6b	37.2x	37.4x	6.3x
Mon, 01 May 2023	CHF 59.1b	CHF 9.7b	CHF 1.6b	40.9x	36.2x	6.1x

Price to Earnings Ratio

36.2x

Mon, 01 May 2023

Current Industry PE

Investors are pessimistic on the Swiss Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 42.2x which is lower than its 3-year average PE of 46.1x.

The industry is trading close to its 3-year average PS ratio of 5.1x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have declined 11% per year over the last three years.
Meanwhile revenues have remained mostly flat.
This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.